List view / Grid view
13 October 2015 | By Victoria White
Cinryze is being studied as an adjunct treatment to Donor Specific Antibodies (DSA) reduction therapy in kidney transplant patients with acute antibody mediated rejection...
13 October 2015 | By Daiichi Sankyo
Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms...
13 October 2015 | By Victoria White
Five abstracts have highlighted the use of Eisai’s eribulin and lenvatinib in rare cancers at the German Association of Hematology and Oncology Meeting...
13 October 2015 | By Victoria White
Researchers have shown the bowel cancer can be assigned into different "consensus molecular subtypes"...
13 October 2015 | By Quotient Clinical
Quotient Clinical has announced that CEO Mark Egerton has received an EY Entrepreneur of the Year® 2015 UK Award...
13 October 2015 | By Victoria White
The findings come from the third part of the CPhI Worldwide 2015 annual report (entitled: ‘Push-pull factors on growth’)...
12 October 2015 | By Victoria White
Lilly has said that it will conclude studies of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease...
12 October 2015 | By Victoria White
In a Phase 3 trial, Opdivo demonstrated superior overall survival (OS) in previously treated metastatic non-squamous NSCLC compared to chemotherapy...
12 October 2015 | By Victoria White
The medicines accepted by the SMC include Herceptin for stomach cancer, radium 223 (Xofigo) and abiraterone (Zytiga) for prostate cancer, and nintedanib (Ofev) for idiopathic pulmonary fibrosis
12 October 2015 | By Black Swan Analysis
Black Swan Analysis has been shortlisted as the 'Micro Business of the Year' for the 2015 Growing Business Awards...
12 October 2015 | By Victoria White
Results from a Phase 4 study show that denosumab achieved greater gains in bone mineral density than zoledronic acid in postmenopausal women with osteoporosis...
12 October 2015 | By Victoria White
Cosentyx is the first fully human interleukin-17A (IL-17A) inhibitor approved in Europe and the US to treat adult moderate-to-severe plaque psoriasis...
12 October 2015 | By Victoria White
Intranasal glucagon, currently in Phase III trials, uses a glucagon nasal powder formulation that is delivered in an emergency situation...
9 October 2015 | By Victoria White
#CPhIChat is an industry-wide Tweetchat for pharma professionals working across the supply chain, aimed to stimulate conversations on key industry issues...
9 October 2015 | By Victoria White
This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab...
